Oruka Therapeutics, Inc.
ORKA
$111.04
$2.922.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.85M | 7.29M | 6.79M | 5.12M | 4.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.11M | 36.43M | 34.43M | 34.11M | 28.43M |
| Operating Income | -50.11M | -36.43M | -34.43M | -34.11M | -28.43M |
| Income Before Tax | -41.21M | -31.82M | -29.58M | -30.28M | -24.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.21M | -31.82M | -29.58M | -30.28M | -24.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.21M | -31.82M | -29.58M | -30.28M | -24.57M |
| EBIT | -50.11M | -36.43M | -34.43M | -34.11M | -28.43M |
| EBITDA | -50.06M | -36.39M | -34.40M | -34.09M | -28.41M |
| EPS Basic | -0.55 | -0.48 | -0.45 | -0.55 | -0.46 |
| Normalized Basic EPS | -0.41 | -0.36 | -0.34 | -0.43 | -0.36 |
| EPS Diluted | -0.55 | -0.48 | -0.45 | -0.55 | -0.46 |
| Normalized Diluted EPS | -0.41 | -0.36 | -0.34 | -0.43 | -0.36 |
| Average Basic Shares Outstanding | 62.87M | 55.17M | 54.42M | 44.07M | 42.10M |
| Average Diluted Shares Outstanding | 62.87M | 55.17M | 54.42M | 44.07M | 42.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |